145 related articles for article (PubMed ID: 327518)
21. Non steroidal anti-inflammatory drugs. Risk factors versus benefits.
Savvas P; Brooks PM
Aust Fam Physician; 1991 Dec; 20(12):1726-9, 1732-3. PubMed ID: 1805774
[TBL] [Abstract][Full Text] [Related]
22. From computer modeling to FDA approval: research strategy for the discovery of new anti-arthritic drugs.
Ackerman NR
Del Med J; 1988 Nov; 60(11):665-6. PubMed ID: 3068079
[No Abstract] [Full Text] [Related]
23. [Comparison of the effects of phenylbutazone and a combination preparation (Exrheudon) in rheumatic diseases].
Engel P
MMW Munch Med Wochenschr; 1977 Jan; 119(3):93-4. PubMed ID: 403430
[No Abstract] [Full Text] [Related]
24. [Various aspects of the treatment with non-steroidal anti- inflammatory drugs].
Gritsiuk AI; Angelutsa PA; Viktorov AP
Revmatologiia (Mosk); 1989; (3):51-6. PubMed ID: 2609060
[No Abstract] [Full Text] [Related]
25. Protocol for evaluation of nonsteroidal antiinflammatory drugs.
Brooks PM
J Rheumatol Suppl; 1994 Sep; 41():82-5. PubMed ID: 7799393
[No Abstract] [Full Text] [Related]
26. Anti-inflammatory efficacy versus gastrointestinal safety: a dilemma resolved? Introduction.
Bach GL
Scand J Rheumatol Suppl; 1992; 96():5-6. PubMed ID: 1439625
[No Abstract] [Full Text] [Related]
27. Key developments in rheumatology.
Panthakalam S; Pal B
Practitioner; 2000 Dec; 244(1617):1024-6, 1029-32. PubMed ID: 11220170
[No Abstract] [Full Text] [Related]
28. [Hyperpermeability of the small intestine mucosa after prolonged application of non-steroidal anti-inflammatory drugs in patients with rheumatic diseases].
Lebedeva VV; Gmoshinskiĭ IV; Mazo VK; Murav'ev IuV
Eksp Klin Gastroenterol; 2008; (2):16-21. PubMed ID: 19148987
[No Abstract] [Full Text] [Related]
29. [Report of a controlled clinical trial of a new synthetic drug, parsalmide, in rheumatic arthropathies (inflammatory and degenerative)].
Sanguinetti CM; Bonifazi F
Minerva Med; 1976 Oct; 67(52):3391-5. PubMed ID: 792738
[TBL] [Abstract][Full Text] [Related]
30. Fenbufen and indomethacin in the treatment of rheumatoid arthritis. A comparative double-blind, crossover study.
Ammitzbøll F
Scand J Rheumatol Suppl; 1979; (23):5-10. PubMed ID: 373083
[No Abstract] [Full Text] [Related]
31. [Free oxygen radicals. Their role in the physiopathology of rheumatic diseases and therapeutic implications].
Allegrezza Giulietti A; Muti S; Piergiacomi G
Clin Ter; 1987 Sep; 122(6):445-57. PubMed ID: 2972458
[No Abstract] [Full Text] [Related]
32. [Evaluation of the effect of therapy with Turganil in 1,240 patients].
Zgradić I; Popović M; Lasić G
Med Pregl; 1993; 46(11-12):445-8. PubMed ID: 7997202
[TBL] [Abstract][Full Text] [Related]
33. [Clinical study of acetylsalicylate of lysine (solusprin) in rheumatic diseases].
Castillo Ojugas A; San Román Terán J; Traver Aguilar MD
Rev Esp Reum Enferm Osteoartic; 1977; 20(3):189-205. PubMed ID: 337424
[No Abstract] [Full Text] [Related]
34. [Flurbiprofen: pharmacological characteristics and clinical effectiveness].
Karateev DE; Nasonova VA; Ivanova MM
Klin Med (Mosk); 1998; 76(12):51-6. PubMed ID: 10067295
[No Abstract] [Full Text] [Related]
35. [Ant-inflammatory or antirheumatic agents? The pharmacological activity and therapeutic effectiveness of non-steroidal anti-inflammatory drugs: comparative study. I].
Mariani L; Baratelli M
Clin Ter; 1980 Jan; 92(2):105-26. PubMed ID: 6966996
[No Abstract] [Full Text] [Related]
36. [Clinical evaluation of proglumetacin malate in rheumatoid arthritis--a multi-institutional cooperative study].
Ryumachi; 1986 Oct; 26(5):377-88. PubMed ID: 3299753
[No Abstract] [Full Text] [Related]
37. [A clinical evaluation of CN-100 in patients with rheumatoid arthritis].
Yoshizawa H; Ogawa N; Azuma T
Ryumachi; 1991 Feb; 31(1):127-38. PubMed ID: 1857991
[No Abstract] [Full Text] [Related]
38. [Criteria of the effectiveness of antirheumatic agents in controlled clinical trials].
Pavelka K
Ter Arkh; 1982; 54(6):106-9. PubMed ID: 7051392
[No Abstract] [Full Text] [Related]
39. [Therapeutic effects of non-steroid anti-inflammatory agents, with special reference to 2-4(4-isobutylphenyl)-propionic acid].
Cremoncini C; Mola V
Minerva Med; 1973 Jun; 64(46):2423-35. PubMed ID: 4579327
[No Abstract] [Full Text] [Related]
40. [2-(4-Isobutylphenyl)-propionic acid in the treatment of rheumatic diseases: clinical effects and tolerance].
Viara M
Minerva Med; 1973 Jun; 64(47):2513-4. PubMed ID: 4579843
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
